歐科雲鏈(01499.HK):擬4500萬港元出售合富環球全部股權
格隆匯12月22日丨歐科雲鏈(01499.HK)宣佈,於2023年12月22日,賣方(公司直接全資附屬公司)與買方彩向控股有限公司訂立買賣協議,據此,賣方同意出售而買方同意收購待售股份,即出售公司的全部已發行股本,代價為4500萬港元。出售事項已於2023年12月22日訂立買賣協議時完成。於完成後,賣方已不再擁有出售集團任何權益,而出售集團之財務業績將不會再併入集團業績。
據悉,出售公司合富環球為一間於英屬處女羣島註冊成立之有限公司,於緊接完成前為公司的間接全資附屬公司。出售公司的主要業務為投資控股。出售公司持有忠信建築全部已發行股本。出售集團主要從事提供建築廢物處理服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.